SCHEMBL729315

SCHEMBL729315

Clc1ccc2cccc(OCc3ccccc3)c2n1

nearest known ligand 0.68

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.54
KMT2A Q03164 5/20 0.54
KDM4E B2RXH2 4/20 0.53
MAPT P10636 3/20 0.53
CCR6 P51684 1/20 0.53
ALDH1A1 P00352 2/20 0.51
HPGD P15428 2/20 0.51
HTT P42858 1/20 0.51
NPC1 O15118 2/20 0.50
RAB9A P51151 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
MAPK1 P28482 1/20 0.49
TDP1 Q9NUW8 1/20 0.49
HDAC3 O15379 2/20 0.47
HDAC4 P56524 2/20 0.47
HDAC1 Q13547 2/20 0.47
HDAC7 Q8WUI4 2/20 0.47
HDAC2 Q92769 2/20 0.47
HDAC10 Q969S8 2/20 0.47
HDAC11 Q96DB2 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1012890 0.84 NCF1 (0.63) KDM4EMAPTCCR6PLAUNCF1
Bromide SCHEMBL5753024 0.83 NCF1 (0.61) KDM4EMAPTCCR6PLAUNCF1
SCHEMBL9951781 0.83 MEN1 (0.55) MEN1KMT2AKDM4EMAPTCCR6
SCHEMBL22901568 0.82 MAPT (0.54) MEN1KMT2AMAPTHTTSMN1; SMN2
SCHEMBL28622872 0.82 MEN1 (0.51) MEN1KMT2AKDM4EMAPTCCR6
SCHEMBL4627344 0.81 KDM4E (0.48) MEN1KMT2AKDM4EMAPTCCR6
SCHEMBL3949886 0.81 MEN1 (0.78) MEN1KMT2AKDM4EMAPTCCR6
SCHEMBL731221 0.81 KDM4E (0.56) MEN1KMT2AKDM4EMAPTCCR6
SCHEMBL18438857 0.81 MEN1 (0.61) MEN1KMT2AKDM4EMAPTCCR6
SCHEMBL28284853 0.81 MEN1 (0.59) MEN1KMT2AKDM4EMAPTCCR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107382983-B Synthesis method of medicine for treating leukemia 扬州市三药制药有限公司 2020-08-07 CN claimed
CN-107382983-A A kind of synthetic method for treating leukemia medicament 扬州市三药制药有限公司 2017-11-24 CN claimed
EP-1501801-B1 2,6-QUINOLINYL AND 2,6-NAPHTHYL DERIVATIVES AND THEIR USE IN THE TREATMENT OF VLA-4 DEPENDENT DISEASES UCB PHARMA SA (BE) 2008-01-23 EP claimed
EP-4724431-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND USE THEREOF Beone Medicines I GmbH (CH) 2026-04-15 EP disclosed
US-12600719-B2 Salt inducible kinase inhibitors THE GENERAL HOSPITAL CORPORATION (US) 2026-04-14 US disclosed
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF BEONE MEDICINES I GMBH (CH) 2026-03-26 US disclosed
EP-4660192-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2025-12-10 EP disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS THE GENERAL HOSPITAL CORPORATION 2024-01-25 US disclosed
EP-4192459-A1 SALT INDUCIBLE KINASE INHIBITORS The General Hospital Corporation (US) 2023-06-14 EP disclosed
EP-1594858-A2 NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS Pfizer Products Inc. (US) 2005-11-16 EP disclosed
EP-1583537-A2 PIPERIDINE COMPOUNDS AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2005-10-12 EP disclosed
CN-1678604-A Novel benzoimidazole derivatives useful as antiproliferative agents PFIZER PROD INC (US) 2005-10-05 CN disclosed
US-20050124599-A1 Novel benzoimidazole derivatives useful as antiproliferative agents PFIZER INC. 2005-06-09 US disclosed
WO-2004020431-A2 NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS PFIZER PRODUCTS INC. (US) 2004-03-11 WO disclosed
WO-2004002490-A2 PIPERIDINE COMPOUNDS AS ANTIBACTERIALS GLAXO GROUP LIMITED (GB) 2004-01-08 WO disclosed
CN-1402721-A Novel benzimidazole derivatives as antiproliferative agents PFIZER PROD INC (US) 2003-03-12 CN disclosed
EP-1235825-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS Pfizer Products Inc. (US) 2002-09-04 EP disclosed
WO-2001040217-A1 NOVEL BENZOIMIDAZOLE DERIVATIVES USEFUL AS ANTIPROLIFERATIVE AGENTS PFIZER PRODUCTS INC. (US) 2001-06-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124599-A1 Novel benzoimidazole derivatives useful as antiproliferative agents CCNI, CCNT1, CCNA1 MEN1 1619/4885KMT2A 1766/4885KDM4E 441/4885
US-20260085053-A1 BENZOFURAN DERIVATIVES AS SIK INHIBITORS AND THE USE THEREOF SIK1, CHUK, SIK2 MEN1 4791/4885KMT2A 3438/4885KDM4E 2280/4885
US-12600719-B2 Salt inducible kinase inhibitors GRK6, SGK1, CSNK1A1 MEN1 4306/4885KMT2A 2360/4885KDM4E 2348/4885
US-20240025892-A1 SALT INDUCIBLE KINASE INHIBITORS SGK1, SGK2, SIK1 MEN1 4351/4885KMT2A 1365/4885KDM4E 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.